These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

523 related articles for article (PubMed ID: 30588192)

  • 1. Bleeding Risk of Warfarin and Direct Oral Anticoagulants in Younger Population: A Historical Cohort Study Using a Japanese Claims Database.
    Yokoyama S; Tanaka Y; Nakagita K; Hosomi K; Takada M
    Int J Med Sci; 2018; 15(14):1686-1693. PubMed ID: 30588192
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Comparative risk of gastrointestinal bleeding with dabigatran, rivaroxaban, and warfarin: population based cohort study.
    Abraham NS; Singh S; Alexander GC; Heien H; Haas LR; Crown W; Shah ND
    BMJ; 2015 Apr; 350():h1857. PubMed ID: 25910928
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Intracranial Hemorrhage in Deep Vein Thrombosis/Pulmonary Embolus Patients Without Atrial Fibrillation.
    Lamsam L; Sussman ES; Iyer AK; Bhambhvani HP; Han SS; Skirboll S; Ratliff JK
    Stroke; 2018 Aug; 49(8):1866-1871. PubMed ID: 29991654
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Oral anticoagulants usage in Japanese patients aged 18-74 years with non-valvular atrial fibrillation: a retrospective analysis based on insurance claims data.
    Ohshima A; Koyama T; Ogawa A; Zamami Y; Tanaka HY; Kitamura Y; Sendo T; Hinotsu S; Miller MW; Kano MR
    Fam Pract; 2019 Nov; 36(6):685-692. PubMed ID: 31329899
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Comparative effectiveness and safety of warfarin and dabigatran in patients with non-valvular atrial fibrillation in Japan: A claims database analysis.
    Koretsune Y; Yamashita T; Yasaka M; Ono Y; Hirakawa T; Ishida K; Kuroki D; Sumida T; Urushihara H
    J Cardiol; 2019 Mar; 73(3):204-209. PubMed ID: 30477926
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Predicting major bleeding among hospitalized patients using oral anticoagulants for atrial fibrillation after discharge.
    Qazi JZ; Schnitzer ME; Côté R; Martel MJ; Dorais M; Perreault S
    PLoS One; 2021; 16(3):e0246691. PubMed ID: 33657116
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Stroke and bleeding with non-vitamin K antagonist oral anticoagulant or warfarin treatment in patients with non-valvular atrial fibrillation: a population-based cohort study.
    Forslund T; Wettermark B; Andersen M; Hjemdahl P
    Europace; 2018 Mar; 20(3):420-428. PubMed ID: 28177459
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Cardiovascular, bleeding, and mortality risks in elderly Medicare patients treated with dabigatran or warfarin for nonvalvular atrial fibrillation.
    Graham DJ; Reichman ME; Wernecke M; Zhang R; Southworth MR; Levenson M; Sheu TC; Mott K; Goulding MR; Houstoun M; MaCurdy TE; Worrall C; Kelman JA
    Circulation; 2015 Jan; 131(2):157-64. PubMed ID: 25359164
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Risk of gastrointestinal bleeding associated with oral anticoagulants: population based retrospective cohort study.
    Chang HY; Zhou M; Tang W; Alexander GC; Singh S
    BMJ; 2015 Apr; 350():h1585. PubMed ID: 25911526
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Prescription patterns of oral anticoagulants for patients with non-valvular atrial fibrillation: experience at a Japanese single institution.
    Tagaya M; Yoshikawa D; Sugishita Y; Yamauchi F; Ito T; Kamada T; Yoshinaga M; Mukaide D; Fujiwara W; Yokoi H; Hayashi M; Watanabe E; Ishii J; Ozaki Y; Izawa H
    Heart Vessels; 2016 Jun; 31(6):957-62. PubMed ID: 26022376
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Gastrointestinal Bleeding From Oral Anticoagulant Therapy Among Japanese Patients With Atrial Fibrillation Identified From the SAKURA Atrial Fibrillation Registry.
    Murata N; Okumura Y; Nagashima K; Fukamachi D; Yokoyama K; Matsumoto N; Tachibana E; Kuronuma K; Oiwa K; Matsumoto M; Kojima T; Hanada S; Nomoto K; Arima K; Takahashi F; Kotani T; Ikeya Y; Fukushima S; Itou S; Kondo K; Chiku M; Ohno Y; Onikura M; Hirayama A;
    Circ J; 2020 Aug; 84(9):1475-1482. PubMed ID: 32713873
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Effectiveness and Safety of Direct Oral Anticoagulants in Relation to Temporal Changes in Their Use.
    Lee SR; Choi EK; Kwon S; Jung JH; Han KD; Cha MJ; Oh S; Lip GYH
    Circ Cardiovasc Qual Outcomes; 2020 Mar; 13(3):e005894. PubMed ID: 32160790
    [TBL] [Abstract][Full Text] [Related]  

  • 13. A comparison of the safety and effectiveness of dabigatran and warfarin in non-valvular atrial fibrillation patients in a large healthcare system.
    Villines TC; Schnee J; Fraeman K; Siu K; Reynolds MW; Collins J; Schwartzman E
    Thromb Haemost; 2015 Nov; 114(6):1290-8. PubMed ID: 26446456
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Temporal Trends in the Use and Comparative Effectiveness of Direct Oral Anticoagulant Agents Versus Warfarin for Nonvalvular Atrial Fibrillation: A Canadian Population-Based Study.
    Yu AYX; Malo S; Svenson LW; Wilton SB; Hill MD
    J Am Heart Assoc; 2017 Oct; 6(11):. PubMed ID: 29080863
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Comparison of the short-term risk of bleeding and arterial thromboembolic events in nonvalvular atrial fibrillation patients newly treated with dabigatran or rivaroxaban versus vitamin K antagonists: a French nationwide propensity-matched cohort study.
    Maura G; Blotière PO; Bouillon K; Billionnet C; Ricordeau P; Alla F; Zureik M
    Circulation; 2015 Sep; 132(13):1252-60. PubMed ID: 26199338
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Dabigatran use in elderly patients with atrial fibrillation.
    Avgil-Tsadok M; Jackevicius CA; Essebag V; Eisenberg MJ; Rahme E; Behlouli H; Pilote L
    Thromb Haemost; 2016 Jan; 115(1):152-60. PubMed ID: 26354766
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Renal function and risk of stroke and bleeding in patients undergoing catheter ablation for atrial fibrillation: Comparison between uninterrupted direct oral anticoagulants and warfarin administration.
    Yanagisawa S; Inden Y; Fujii A; Ando M; Funabiki J; Murase Y; Takenaka M; Otake N; Ikai Y; Sakamoto Y; Shibata R; Murohara T
    Heart Rhythm; 2018 Mar; 15(3):348-354. PubMed ID: 29107192
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Bleeding risk of apixaban, dabigatran, and low-dose rivaroxaban compared with warfarin in Japanese patients with non-valvular atrial fibrillation: a propensity matched analysis of administrative claims data.
    Kohsaka S; Murata T; Izumi N; Katada J; Wang F; Terayama Y
    Curr Med Res Opin; 2017 Nov; 33(11):1955-1963. PubMed ID: 28857611
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Effects of Oral Anticoagulants on Patients With Atrial Fibrillation Aged 90 Years and Older: Comparison Among Direct Oral Anticoagulant, Warfarin Anticoagulant, and Nonanticoagulation.
    Yamaji H; Higashiya S; Murakami T; Hina K; Kawamura H; Murakami M; Kamikawa S; Hirohata S; Kusachi S
    J Cardiovasc Pharmacol; 2019 Sep; 74(3):246-254. PubMed ID: 31498193
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Safety of direct oral anticoagulants vs warfarin in patients with chronic liver disease and atrial fibrillation.
    Goriacko P; Veltri KT
    Eur J Haematol; 2018 May; 100(5):488-493. PubMed ID: 29444357
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 27.